<DOC>
	<DOCNO>NCT01224821</DOCNO>
	<brief_summary>Study RIT-II-001 phase II , multicenter study safety , tumor organ dosimetry , dosimetry method , efficacy Iodine-131 Anti-B1 Antibody treatment patient low-grade transformed low-grade non-Hodgkin 's lymphoma ( NHL ) . The primary objective study demonstrate site could accurately conduct whole body dosimetry require safe effective dose Iodine-131 Anti-B1 Antibody . Additional objective study evaluate efficacy , dosimetry , safety Iodine-131 Anti-B1 Antibody .</brief_summary>
	<brief_title>Dosimetry/Validation Study 131Iodine-Anti B1 ( Murine ) Radioimmunotherapy Chemotherapy Refractory Low Grade B Cell Lymphomas Low Grade Lymphomas That Have Transformed Higher Grade Histologies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Inclusion Criteria Patients must histologically confirm diagnosis lowgrade nonHodgkin 's Bcell lymphoma lowgrade lymphoma transform intermediate , highgrade lymphoma ( transformed lymphoma ) accord Working Formulation Clinical Usage ( IWF A , B , C ) . Patients must evidence tumor tissue express CD20 antigen . Patients must progressive disease either lowgrade transform lymphoma within one year completion last chemotherapy regimen administer . Patients must previously treat least one chemotherapy regimen include anthracycline anthracenedione . Patients must performance status least 60 % Karnofsky Scale anticipate survival least three month . Patients must absolute granulocyte count 1,500 /mm3 platelet count 100,000 /mm3 within seven day study entry . These blood count must sustain without support hematopoietic cytokine transfusion blood product . Patients must normal renal function ( creatinine le 2.0 mg/dL ) hepatic function ( bilirubin le 2.0 mg/dL ) within seven day study entry . Patients must bidimensionally measurable evaluable progressive lymphoma disease ( least 25 % increase tumor size new site disease compare last best disease response ) . Progression must occur within 12 month precede response . Patients must least 18 year age . Patients must give write informed consent sign approve informed consent form prior study entry . Exclusion Criteria Patients average 25 % intertrabecular marrow space involve lymphoma bone marrow biopsy specimen assess microscopically study entry . Patients receive cytotoxic chemotherapy , radiation therapy , immunosuppressant , cytokine treatment within FOUR week prior study entry ( six week nitrosourea compound ) exhibit persistent clinical evidence toxicity . The use steroid must discontinue ( except maintenancedose steroid ) least one week prior study entry patient must show evidence stable progressive disease . Patients prior hematologic stem cell transplant follow highdose chemotherapy chemo/radiotherapy . Patients obstructive hydronephrosis . Patients evidence active infection require intravenous antibiotic time study entry . Patients New York Heart Association class 3 4 heart disease serious illness would preclude evaluation . Patients prior malignancy lymphoma , except adequately treated skin cancer , situ cervical cancer , cancer patient diseasefree five year . Patients know HIV infection . Patients know brain leptomeningeal metastasis . Patients pregnant . Patients childbearing potential must undergo pregnancy test within seven day study entry . Males female must agree use effective contraception study . Patients previous allergic reaction iodine . This include IV contrast material . Patients previously give monoclonal polyclonal antibody foreign specie either diagnostic therapeutic purpose . This include engineered chimeric humanize antibody . Patients previously receive radioimmunotherapy . Patients progressive disease field previously irradiated 3500 cGy . Patients another protocol involve nonapproved drug biologics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>iodine I 131 tositumomab</keyword>
	<keyword>anti-B1 Antibody</keyword>
	<keyword>Bexxar</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>tositumomab</keyword>
</DOC>